Gail Farfel
Direttore/Membro del Consiglio presso DURECT CORPORATION
Patrimonio netto: 118 764 $ in data 31/05/2024
Profilo
Gail M.
Farfel is currently a Director at DURECT Corp., PrintedArt, FAAH Pharma, Inc., and the American Society For Experimental Neurotherapeutics.
Previously, she served as the President, Chief Executive Officer & Director at ProMIS Neurosciences, Inc., Senior Associate Director at Pfizer Inc., Director at Zogenix International Ltd., Director at AVROBIO, Inc., Chief Clinical & Regulatory Officer at Marinus Pharmaceuticals, Inc., VP-Therapeutic Area & Head-Neuroscience at Novartis Pharmaceuticals Corp., Global Team Lead at Pfizer Pharmaceuticals, Inc., and President at G Meredith Consulting LLC.
She also held the position of Chief Development Officer & Executive VP at Zogenix, Inc. Dr. Farfel obtained her undergraduate degree from the University of Virginia and her doctorate from The University of Chicago.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 23/08/2023 | 55 192 ( 0.29% ) | 101 664 $ | 31/05/2024 | |
DURECT CORPORATION
0.03% | 26/03/2024 | 10 000 ( 0.03% ) | 17 100 $ | 31/05/2024 |
-.--% | 07/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Gail Farfel
| Società | Posizione | Inizio |
|---|---|---|
| DURECT CORPORATION | Direttore/Membro del Consiglio | 25/04/2019 |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Direttore/Membro del Consiglio | - |
| American Society For Experimental Neurotherapeutics | Direttore/Membro del Consiglio | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Direttore/Membro del Consiglio | 07/08/2014 |
Precedenti posizioni note di Gail Farfel
| Società | Posizione | Fine |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Direttore/Membro del Consiglio | 20/05/2024 |
| PROMIS NEUROSCIENCES, INC. | Amministratore Delegato | 30/12/2023 |
| ZOGENIX, INC. | Corporate Officer/Principal | 01/09/2022 |
| MARINUS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2015 |
| G Meredith Consulting LLC | Presidente | 01/12/2012 |
Formazione di Gail Farfel
| University of Virginia | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Aziende private | 9 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
| G Meredith Consulting LLC | |
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
| American Society For Experimental Neurotherapeutics |
- Borsa valori
- Insiders
- Gail Farfel
